Kriya visheshan kise kahate hain uske prakar. From California to North Carolina, our teammates bring creativity, leadership, and a spirit of collaboration to their work every day. Sep 12, 2024 · KRIYA-586 is an investigational adeno-associated virus (AAV) gene therapy product engineered to express an antibody that inhibits Insulin-Like Growth Factor 1 Receptor (IGF1R), a key target implicated in the pathogenesis of TED. Kriya is targeting diseases that impact millions of people worldwide and represent areas of high unmet need. Kriya is developing KRIYA 839, a potential one-time gene therapy for type 1 diabetes expressing insulin and glucokinase, designed to be delivered intramuscularly with the objective of driving durable glycemic control and reducing or eliminating the need for exogenous insulin. (“Kriya”), a clinical-stage biopharmaceutical company developing gene therapies to address common chronic diseases of high unmet need, today announced the closing of a $320 million Series D financing. Kriya is developing a portfolio of one-time gene therapies in ophthalmology, metabolic disease and neurology. – September 10, 2025 – Kriya Therapeutics, Inc. We target validated biological pathways with innovative gene therapy approaches that have the potential to deliver transformative benefits. May 8, 2025 · Kriya is developing KRIYA-825, a potential one-time gene therapy for Geographic Atrophy (GA) that expresses a fusion protein designed to inhibit the activity of complement C3 and C5, with the objective of slowing GA lesion growth and vision loss. Jun 18, 2024 · Kriya shares the latest news on our pipeline of life-changing gene therapies to address common diseases. Jul 26, 2023 · With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $600 million in committed capital, which will be used to advance a broad pipeline of gene therapies for ophthalmology, neurology and metabolic disease. Kriya’s team of gene therapy pioneers and biopharma veterans is building a pipeline to address common diseases. C. . Careers Kriya is Changing the Future of Gene Therapy We have an ambitious set of goals, but our confidence – and our inspiration – stems from our people. Kriya is targeting diseases that impact millions of people worldwide and represent areas of high unmet need. Sep 10, 2025 · RESEARCH TRIANGLE PARK, N. bslrc fpucy iklasq ajzo cplu nzfkb xtipkv uvmchw qszl rlfpc